Back to News
Market Impact: 0.2
Bionyra Pharma Announces First Healthy Volunteers Dosed in Phase 1 Study of BYN-001, a Long-Acting IL-25 Antibody for Atopic Dermatitis
Source: Business Wire
Healthcare & Biotech
Bionyra Pharma announced that the first healthy volunteers have been dosed in a Phase 1 study of BYN-001, a long-acting IL-25 antibody being developed for atopic dermatitis. The milestone advances the program into initial human clinical testing, but no safety, efficacy, dosing, or financial data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- Biotech stocks are surging. How investors can play the new drug innovation boom
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
- J&J prostate cancer drug shows promising tumor responses in early trial
- Pfizer reports phase 2 data for 25-valent pneumococcal vaccine
- Fact vs. fiction: Doctors share whether peptides are safe and effective
- Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer